Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.74 |
| ▸ | MAPT | P10636 | 9/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.74 |
| ▸ | HPGD | P15428 | 5/20 | 0.74 |
| ▸ | GAA | P10253 | 2/20 | 0.74 |
| ▸ | LMNA | P02545 | 1/20 | 0.74 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.58 |
| ▸ | USP2 | O75604 | 1/20 | 0.58 |
| ▸ | FLT3 | P36888 | 1/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | CASP1 | P29466 | 1/20 | 0.55 |
| ▸ | CASP7 | P55210 | 1/20 | 0.55 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL135846 | 0.99 | TDP1 (0.72) | TDP1MAPTALDH1A1HPGDGAA | |
| SCHEMBL133029 | 0.97 | TDP1 (0.70) | TDP1MAPTALDH1A1HPGDGAA | |
| SCHEMBL3656064 | 0.87 | ALDH1A1 (0.81) | TDP1MAPTALDH1A1HPGDGAA | |
| SCHEMBL4060800 | 0.86 | TDP1 (0.71) | TDP1MAPTALDH1A1HPGDGAA | |
| SCHEMBL135449 | 0.86 | TDP1 (0.71) | TDP1MAPTALDH1A1HPGDGAA | |
| SCHEMBL3768107 | 0.85 | TDP1 (0.74) | TDP1MAPTALDH1A1HPGDGAA | |
| SCHEMBL3768395 | 0.85 | TDP1 (0.74) | TDP1MAPTALDH1A1HPGDGAA | |
| SCHEMBL138711 | 0.85 | TDP1 (0.74) | TDP1MAPTALDH1A1HPGDGAA | |
| T-62 SCHEMBL135569 | 0.85 | TDP1 (1.00) | TDP1MAPTALDH1A1HPGDGAA | |
| SCHEMBL1637546 | 0.85 | ALDH1A1 (1.00) | TDP1MAPTALDH1A1HPGDGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113782751-B | Preparation method of high-flexibility carbon/resin composite material | 宁波信远材料科技股份有限公司 | 2023-08-11 | — | — | CN | claimed |
| US-20100317709-A1 | SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR COMPOUNDS | UNIVERSITEIT LEIDEN | 2010-12-16 | — | — | US | claimed |
| CN-113782751-B | Preparation method of high-flexibility carbon/resin composite material | 宁波信远材料科技股份有限公司 | 2023-08-11 | — | — | CN | disclosed |
| EP-2430029-B1 | THIENO[2,3-B]PYRIDINE DERIVATIVES AS VIRAL REPLICATION INHIBITORS | UNIV LEUVEN KATH (BE) | 2018-01-10 | — | — | EP | disclosed |
| US-9499563-B2 | Thieno [2, 3-B] pyridine derivatives as viral replication inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2016-11-22 | — | — | US | disclosed |
| US-20150336965-A1 | NOVEL ANTIVIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2015-11-26 | — | — | US | disclosed |
| US-9132129-B2 | Antiviral compounds | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2015-09-15 | — | — | US | disclosed |
| US-20140296272-A1 | THIENO [2, 3-B] PYRIDINE DERIVATIVES AS VIRAL REPLICATION INHIBITORS | CISTIM LEUVEN VZW (BE) | 2014-10-02 | — | — | US | disclosed |
| US-8785638-B2 | Thieno [2, 3-B] pyridine derivatives as viral replication inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2014-07-22 | — | — | US | disclosed |
| US-20130245049-A1 | Novel Antiviral Compounds | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2013-09-19 | — | — | US | disclosed |
| US-20120059028-A1 | THIENO [2, 3-B] PYRIDINE DERIVATIVES AS VIRAL REPLICATION INHIBITORS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2012-03-08 | — | — | US | disclosed |
| US-20100317709-A1 | SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR COMPOUNDS | UNIVERSITEIT LEIDEN | 2010-12-16 | — | — | US | disclosed |
| US-20090041839-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PAIN | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2009-02-12 | — | — | US | disclosed |
| US-20090023799-A1 | CRYSTALS OF (2-AMINO-4,5,6,7-TETRAHYDROBENZO[b]THIEN-3-YL)(4-CHLOROPHENYL)METHANONE | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2009-01-22 | — | — | US | disclosed |
| US-20080113969-A1 | COMBINATION THERAPY FOR THE TREATMENT OF PAIN | CREDIT SUISSE AG | 2008-05-15 | — | — | US | disclosed |
| US-20080108622-A1 | COMBINATION THERAPY FOR THE TREATMENT OF PAIN | CREDIT SUISSE AG | 2008-05-08 | — | — | US | disclosed |
| US-20080108603-A1 | COMBINATION THERAPY FOR THE TREATMENT OF PAIN | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2008-05-08 | — | — | US | disclosed |
| WO-2008051760-A2 | COMBINATION THERAPY FOR THE TREATMENT OF PAIN | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2008-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023799-A1 | CRYSTALS OF (2-AMINO-4,5,6,7-TETRAHYDROBENZO[b]THIEN-3-YL)(4-CHLOROPHENYL)METHANONE | ADORA1, ADORA2B, ADORA2A | TDP1 1372/4885MAPT 1940/4885ALDH1A1 720/4885 |
| US-20080113969-A1 | COMBINATION THERAPY FOR THE TREATMENT OF PAIN | ADORA1, ADORA3, OPRL1 | TDP1 2280/4885MAPT 3898/4885ALDH1A1 1275/4885 |
| US-20080108603-A1 | COMBINATION THERAPY FOR THE TREATMENT OF PAIN | ADORA1, ADORA3, OPRL1 | TDP1 2280/4885MAPT 3898/4885ALDH1A1 1275/4885 |
| US-20140296272-A1 | THIENO [2, 3-B] PYRIDINE DERIVATIVES AS VIRAL REPLICATION INHIBITORS | TYMP, DUT, MAVS | TDP1 928/4885MAPT 2061/4885ALDH1A1 1925/4885 |
| US-20080108622-A1 | COMBINATION THERAPY FOR THE TREATMENT OF PAIN | ADORA1, ADORA3, OPRL1 | TDP1 2280/4885MAPT 3898/4885ALDH1A1 1275/4885 |
| US-20100317709-A1 | SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR COMPOUNDS | S1PR3, S1PR1, S1PR5 | TDP1 1316/4885MAPT 4166/4885ALDH1A1 4570/4885 |
| US-20130245049-A1 | Novel Antiviral Compounds | MAVS, EIF2AK2, ZC3HAV1 | TDP1 2102/4885MAPT 2788/4885ALDH1A1 1414/4885 |
| US-20120059028-A1 | THIENO [2, 3-B] PYRIDINE DERIVATIVES AS VIRAL REPLICATION INHIBITORS | TYMP, DUT, MAVS | TDP1 928/4885MAPT 2061/4885ALDH1A1 1925/4885 |
| US-20090041839-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PAIN | ADORA1, ADORA2A, ADORA3 | TDP1 1259/4885MAPT 3488/4885ALDH1A1 2870/4885 |
| US-20150336965-A1 | NOVEL ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | TDP1 2102/4885MAPT 2788/4885ALDH1A1 1414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.